Examining Trends in Biosimilar Development: A Year in Review An Open Discussion of Critical Events and Biosimilar Trends of 2017

Dec 07, 2017
By IQVIA

Register Free: http://www.appliedclinicaltrialsonline.com/act_w/trends

Sponsors of biosimilar products made significant gains in 2017, though Research & Development and commercial challenges remain.  Noteworthy news items included more and novel biosimilar approvals in ICH countries, including the first oncology biosimilar approval. There were also significant U.S. court decisions, such as the elimination of the patent dance, evolving and new innovator protection strategies, and promulgation of additional draft regulatory guidance, including those related to interchangeability and biostatistics.

This webinar will provide attendees an extended period of time to engage biosimilar experts from IQVIA’s Biosimilars Center of Excellence (BCOE) to identify the key issues of 2017 – in a “Year in Review” format. 

 

Speakers:

Raymond Huml, MS, DVM, RAC, Vice President, Head, Global Biosimilars Strategic Planning, Biosimilar Center of Excellence, IQVIA

Dr. Nigel Rulewski, MD, DRCOG, DCH, Vice President, Strategic Drug Development Head, Biosimilar Center of Excellence, IQVIA

 

Date and Time:

Live: Thursday, Dec. 7, 2017 | 11 am EST

After the final airing of the webcast on Dec. 7, 2017 it will be available on demand until Dec. 7, 2018. 

Sponsor: IQVIA

Register Free: http://www.appliedclinicaltrialsonline.com/act_w/trends

native1_300x100
lorem ipsum